A review of the overactive bladder in women and men

Journal of Gender-Specific Medicine

Volumn 6, Issue 4, 2003, Pages 25-29

  Kowalczyk, John ^a  

^a GOOD SAMARITAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; ESTROGEN; MUSCARINIC RECEPTOR BLOCKING AGENT; MUSCLE RELAXANT AGENT; OXYBUTYNIN; SPASMOLYTIC AGENT; TOLTERODINE;

BEHAVIOR MODIFICATION; BLADDER SURGERY; CONSTIPATION; DISEASE SEVERITY; EPIDEMIOLOGICAL DATA; FEEDBACK SYSTEM; FEMALE; HEART PALPITATION; HUMAN; MALE; MEDICAL ASSESSMENT; NERVE STIMULATION; OLIGURIA; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; PREVALENCE; QUALITY OF LIFE; REVIEW; SEX RATIO; SOCIAL ASPECT; SYMPTOMATOLOGY; TREATMENT PLANNING; URINARY FREQUENCY; URINE INCONTINENCE; XEROSTOMIA;

ACTIVITIES OF DAILY LIVING; FEMALE; HEALTH STATUS; HUMANS; MALE; PREVALENCE; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SEX FACTORS; STRESS, PSYCHOLOGICAL; UNITED STATES; URINARY INCONTINENCE;

EID: 0347766015     PISSN: 15237036     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Payne CK. Epidemiology, pathophysiology, and evaluation of urinary incontinene and overactive bladder. Urology 1998;51 (suppl 2A):3-10.
2. Lemack GE. Reversing the tide: Emerging options for treating overactive bladder symptoms in women. Tex Med 1999;11:78-81.
3. Griebling TL, Kreder KJ. Female urinary incontinence: New management tecniques and technologies. Mediguide to Urology 1998; 11(3):1-6.
4. Wein AJ, Rovner ES. The overactive bladder: An overview for primary care health providers. lnt J Fertil 1999;44:56-66.
5. Kowalczyk JJ. Office evaluation of the patient with an overactive urinary bladder. J Am Osteopath Assoc 2000;100(3 suppl):S1-S4.
6. Artibani W. Diagnosis and significance of idiopathic overactive bladder. Urology 1997;50(6A suppl):25-32.
7. Hampel C, Weinhold D, Benken N, et al. Definition of overactive bladder and epidemiology of urinary incontinence. Urology 1997;50(6A suppl):4-14.
8. Nitti VW, Lefkowitz G, Ficazzola M, Dixon CM. Lower urinary tract symptoms in young men: Videourodynamic findings and correlation with noninvasive measures. J Urol 2002;168:135-138.
9. Knutson T, Edlund C, Fall M, Dahlstrand C. BPH with coexisting overactive bladder dysfunction: An everyday urological dilemma. Neurourol Urodyn 2001;20:237-247.
10. Lonsway JM. Surgical and medical treatment options for urge incontinence. J Am Osteopath Assoc 2000;100(3 suppl):S5-S8.
11. Elbadawi A, Yalla SV, Resinick NM. Structural basis of geriatric voiding dysfunction, III: Detrusor overactivity. J Urol 1993;150(5 Pt 2):1668-1680.
12. Appell RA. Clinical efficacy and safety of tolterodine in the treatment a overactive bladder: A pooled analysis. Urology 1997;50(6A suppl):90-96.
13. Wadie BS, Ebrahim el-HE, Gomha MA. The relationship of detrusor instability and symptoms with objective parameters used for diagnosing bladder outlet obstruction: A prospective study. J Urol 2002;168:132-134.
14. de Groat WC. A neurologic basis for the overactive bladder. Urology 1997;50(6A suppl):36-52.
15. Brading AF. A myogenic basis for the overactive bladder. Urology 1997;50(6A suppl):57-67.
16. Chancellor M, Freedman S, Mitcheson HD, et al. Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clin Drug Invest 2000;19(2):83-91.
17. Corcos J, Beaulieu S, Donovan J, et al. Quality of life assessment in men and women with urinary incontinence. J Urol 2002;168:896-905.